-
961
Causal role of immune cells in psoriasis: a Mendelian randomization analysis
Published 2024-03-01Subjects: Get full text
Article -
962
Metabolomic Differences between the Skin and Blood Sera of Atopic Dermatitis and Psoriasis
Published 2022-10-01Subjects: Get full text
Article -
963
Upadacitinib as a treatment for co-existent allergic contact dermatitis and psoriasis
Published 2024-02-01Subjects: Get full text
Article -
964
Exploring the Relationship between Psoriasis and Pregnancy: A Systematic Literature Review
Published 2023-06-01Subjects: Get full text
Article -
965
Drug repositioning prediction for psoriasis using the adverse event reporting database
Published 2023-03-01Subjects: Get full text
Article -
966
Lenalidomide attenuates IMQ-induced inflammation in a mouse model of psoriasis
Published 2022-12-01Subjects: “…Psoriasis…”
Get full text
Article -
967
Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience
Published 2023-12-01Subjects: “…psoriasis…”
Get full text
Article -
968
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Published 2023-05-01Subjects: Get full text
Article -
969
Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review
Published 2017-07-01Subjects: “…psoriasis…”
Get full text
Article -
970
Transcriptomic Profiling of Peripheral Edge of Lesions to Elucidate the Pathogenesis of Psoriasis Vulgaris
Published 2022-04-01“…Our finding provides new insight into signaling pathways in PE skin, which could lead to the discovery of new psoriasis targets.…”
Get full text
Article -
971
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis
Published 2019-04-01Subjects: “…psoriasis…”
Get full text
Article -
972
The link between psoriasis and other diseases based on epidemiological and genetic analyses
Published 2023-09-01Subjects: “…psoriasis…”
Get full text
Article -
973
The causal relationship between psoriasis, psoriatic arthritis, and inflammatory bowel diseases
Published 2022-11-01“…Abstract Psoriasis is more common in patients with inflammatory bowel disease (IBD) than in the general population. …”
Get full text
Article -
974
Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
Published 2023-03-01Subjects: Get full text
Article -
975
Exacerbation of pre‐existence psoriasis following immune checkpoint inhibitor treatment
Published 2022-10-01Get full text
Article -
976
A prediction model identifying glycolysis signature as therapeutic target for psoriasis
Published 2023-05-01Subjects: Get full text
Article -
977
Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis
Published 2021-11-01Subjects: “…psoriasis…”
Get full text
Article -
978
Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis
Published 2019-02-01“…Three main biologics target the IL-17 pathway; these include secukinumab, ixekizumab, brodalumab, all of which are approved for treatment of moderate-to-severe plaque psoriasis. We performed a systematic review of the literature to determine if IL-17 inhibitors are prone to develop anti-drug antibodies (ADA) and how efficacy of treatment is influenced. …”
Get full text
Article -
979
Generalised pustular psoriasis – a case report and review of therapeutic approaches
Published 2014-11-01Subjects: “…psoriasis…”
Get full text
Article -
980
Genetics of Generalized Pustular Psoriasis: Current Understanding and Implications for Future Therapeutics
Published 2023-06-01Subjects: “…psoriasis and genetics…”
Get full text
Article